Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.

Cardiovasc Diabetol · 2018 · PMC5781294 · PMID 29368615

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Recently, a Korean Health Insurance Service Study showed that TZD as a second-line drug to metformin had relatively lower risk of CVD compared to SU, although these findings did not reach statistical significance [ 20 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.